Articles related to METASTASIS

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

“The WOLVERINE meta-analysis provides the strongest evidence to date that MDT improves progression-free survival, radiographic progression-free survival, and castration resistance-free survival.” — Tang et al., The Lancet Oncology

“Our findings highlight that daily diet matters not only for cancer risk but also for how the disease progresses once it has developed… reducing sugary drinks, targeting SORD or repurposing statins may benefit patients with colorectal cancer.” – Jihye Yun, Lead Researcher

ALK7 gives pancreatic cancer cells both the engine to move and the tools to invade…But if we can inhibit ALK7 at the cancer’s earliest and most vulnerable stage, we might see better outcomes for patients.

IL-1B significantly influences breast cancer bone metastasis by promoting EMT, enhancing osteoclast activity, and creating a conducive metastatic niche. Targeting IL-1B in combination with standard therapies shows promising potential to reduce metastatic outgrowth.

Recent findings indicate that pre-WBRT administration of bevacizumab, etoposide, and cisplatin (BEEP) may significantly improve brain-specific progression-free survival in breast cancer patients with brain metastases.